-+ 0.00%
-+ 0.00%
-+ 0.00%

Danuo Pharmaceutical-B (06872) announced interim results. The loss attributable to shareholders of 64,245 million yuan narrowed 17.81% year-on-year

Zhitongcaijing·08/26/2026 09:25:05
Listen to the news

According to the Zhitong Finance App, Danno Pharmaceutical-B (06872) announced interim results for the six months ended June 30, 2026. The group obtained a loss of RMB 64,245 million (same unit value) for the period due to the Company's owners, a year-on-year reduction of 17.81%; R&D expenses of RMB 31.3821 million, an increase of 19% over the previous year; and a loss of 1.49 yuan per share.

According to the announcement, the Group currently has no products approved for commercial sale, nor has it generated any revenue from product sales. During the reporting period, the Group had not recorded profits and generated operating losses.